Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors | ACS Chemical Neuroscience
![Frontiers | The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications Frontiers | The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications](https://www.frontiersin.org/files/MyHome%20Article%20Library/642493/642493_Thumb_400.jpg)
Frontiers | The Role of the Kappa Opioid System in Comorbid Pain and Psychiatric Disorders: Function and Implications
![Frontiers | Dynorphin/kappa opioid receptor system regulation on amygdaloid circuitry: Implications for neuropsychiatric disorders Frontiers | Dynorphin/kappa opioid receptor system regulation on amygdaloid circuitry: Implications for neuropsychiatric disorders](https://www.frontiersin.org/files/MyHome%20Article%20Library/963691/963691_Thumb_400.jpg)
Frontiers | Dynorphin/kappa opioid receptor system regulation on amygdaloid circuitry: Implications for neuropsychiatric disorders
![Research advances in the clinical application of esketamine - Zhang - 2022 - Ibrain - Wiley Online Library Research advances in the clinical application of esketamine - Zhang - 2022 - Ibrain - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/103ce83b-61a0-4811-b4a6-5f5afc65cd98/ibra12019-fig-0001-m.jpg)
Research advances in the clinical application of esketamine - Zhang - 2022 - Ibrain - Wiley Online Library
![Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism | American Journal of Psychiatry Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism | American Journal of Psychiatry](https://ajp.psychiatryonline.org/cms/10.1176/appi.ajp.2018.18020138/asset/images/medium/appi.ajp.2018.18020138f1.gif)
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism | American Journal of Psychiatry
![Opioid Hedonic Hotspot in Nucleus Accumbens Shell: Mu, Delta, and Kappa Maps for Enhancement of Sweetness “Liking” and “Wanting” | Journal of Neuroscience Opioid Hedonic Hotspot in Nucleus Accumbens Shell: Mu, Delta, and Kappa Maps for Enhancement of Sweetness “Liking” and “Wanting” | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/34/12/4239/F3.large.jpg)
Opioid Hedonic Hotspot in Nucleus Accumbens Shell: Mu, Delta, and Kappa Maps for Enhancement of Sweetness “Liking” and “Wanting” | Journal of Neuroscience
Why People Think Ketamine Is An Opioid — Reset Ketamine - Ketamine Infusion Clinic in Palm Springs, California
![Frontiers | Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System Frontiers | Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System](https://www.frontiersin.org/files/Articles/856672/fphar-13-856672-HTML/image_m/fphar-13-856672-g001.jpg)
Frontiers | Traumatic Stress-Induced Vulnerability to Addiction: Critical Role of the Dynorphin/Kappa Opioid Receptor System
![Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors | ACS Chemical Neuroscience Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors | ACS Chemical Neuroscience](https://pubs.acs.org/cms/10.1021/acschemneuro.0c00741/asset/images/large/cn0c00741_0002.jpeg)
Ketamine Metabolite (2R,6R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors | ACS Chemical Neuroscience
![Biomolecules | Free Full-Text | Ketamine Improves Desensitization of µ-Opioid Receptors Induced by Repeated Treatment with Fentanyl but Not with Morphine Biomolecules | Free Full-Text | Ketamine Improves Desensitization of µ-Opioid Receptors Induced by Repeated Treatment with Fentanyl but Not with Morphine](https://www.mdpi.com/biomolecules/biomolecules-12-00426/article_deploy/html/images/biomolecules-12-00426-g001.png)
Biomolecules | Free Full-Text | Ketamine Improves Desensitization of µ-Opioid Receptors Induced by Repeated Treatment with Fentanyl but Not with Morphine
![Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors | SpringerLink Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00213-022-06118-4/MediaObjects/213_2022_6118_Fig2_HTML.png)
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors | SpringerLink
![Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism | Molecular Psychiatry Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism | Molecular Psychiatry](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41380-019-0503-4/MediaObjects/41380_2019_503_Fig1_HTML.png)
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism | Molecular Psychiatry
![Early life stress dysregulates kappa opioid receptor signaling within the lateral habenula - ScienceDirect Early life stress dysregulates kappa opioid receptor signaling within the lateral habenula - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2352289520300576-fx1.jpg)
Early life stress dysregulates kappa opioid receptor signaling within the lateral habenula - ScienceDirect
![Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine - ScienceDirect Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S002432052300437X-ga1.jpg)
Contribution of the opioid system to depression and to the therapeutic effects of classical antidepressants and ketamine - ScienceDirect
![Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? | Neuropsychopharmacology Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? | Neuropsychopharmacology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnpp.2014.261/MediaObjects/41386_2015_Article_BFnpp2014261_Fig1_HTML.jpg)